FASN and neoplasm: The lipase inhibitor orlistat (ORL) prevents the fatty acid synthase (FAS) enzyme from activating its thioesterase domain, which is especially upregulated in many tumor cells, and its inhibition has been shown to suppress tumor growth and metastasis [1,2].